Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

40.76 +4.57 (+12.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Expert Ratings for PTC Therapeutics
Via Benzinga
7 Nasdaq Stocks to Sell Before They Plunge in 2023
While loyalty may be a positive trait in most circumstances, when it comes to Nasdaq stocks to sell, you got to look out for number one. 
Via InvestorPlace
PTC Therapeutics's Return On Capital Employed Overview
According to Benzinga Pro data, during Q3, PTC Therapeutics (NASDAQ:PTCT) posted sales of $217.13 million. Earnings were up 28.12%, but PTC Therapeutics still reported an overall loss of $109.31... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Nuvalent (NASDAQ:NUVL) stock increased by 15.9% to $25.5 during Friday's pre-market session. The company's market cap stands at $1.2 billion. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 74.8% to $0.17 during Wednesday's pre-market session. The company's market cap stands at $14.1 million. 
Via Benzinga
PTC Therapeutics Pauses Enrollment In Huntington's Candidate Trial In US
Via Benzinga
What 5 Analyst Ratings Have To Say About PTC Therapeutics
Within the last quarter, PTC Therapeutics (NASDAQ:PTCT) has observed the following analyst ratings: 
Via Benzinga
Expert Ratings for PTC Therapeutics
Analysts have provided the following ratings for PTC Therapeutics (NASDAQ:PTCT) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
PTC Therapeutics Gets $1B Funding From Blackstone, Shares Fall
Via Benzinga
Reaction Is Overdone For PTC Therapeutics Pausing Huntington Trial Enrollment, Analyst Says
Via Benzinga
Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Analyst Ratings for PTC Therapeutics
Within the last quarter, PTC Therapeutics (NASDAQ:PTCT) has observed the following analyst ratings: 
Via Benzinga
Analyst Ratings for PTC Therapeutics
Analysts have provided the following ratings for PTC Therapeutics (NASDAQ:PTCT) within the last quarter: 
Via Benzinga
Why Edwards Lifesciences Shares Are Trading Lower By Around 17%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) surged 179% to $3.6301. 
Via Benzinga
Marten Transport, Silvergate Capital And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
Via Benzinga
PTC Therapeutics: Q2 Earnings Insights
PTC Therapeutics (NASDAQ:PTCT) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2022
Upgrades 
Via Benzinga
Newman Ferrara LLP Announces Corporate Governance Investigations of PTC Therapeutics (PTCT)
From Newman Ferrara LLP
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
Upgrades 
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
  
Via Benzinga
The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
PTC Stock Has Gained 27% This Week Alone, And It's Still Sprinting
Shares of PTC stock continued a seven-day run Thursday on promising test results for its Duchenne muscular dystrophy treatment. 
Via Investor's Business Daily
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in PTC Therapeutics, Inc. with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.